Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 376Polycystic Ovary Syndrome 41Neoplasm Metastasis 23Endometrial Neoplasms 22Ovarian Neoplasms 16Neoplasms 14Infertility 12Advanced Breast Cancer 10Fallopian Tube Neoplasms 8Carcinoma, Intraductal, Noninfiltrating 8Triple Negative Breast Neoplasms 7Recurrence 7Osteoporosis 7Carcinoma, Ductal, Breast 7Breast Neoplasms, Male 7Breast Diseases 7Carcinoma, Lobular 6Breast Carcinoma In Situ 6Prostatic Neoplasms 5Leiomyoma 4Infertility, Female 4Hereditary Sensory and Autonomic Neuropathies 4Breast Cancer Metastatic 4Arthralgia 4Obesity 3Neoplasms, Hormone-Dependent 3Carcinoma, Ovarian Epithelial 3Carcinoma, Non-Small-Cell Lung 3Anovulation 3Uterine Neoplasms 2

Interventions

camrelizumab 1Surgical Procedures, Operative 1Paclitaxel 1ON123300 1Letrozole 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrioid Endometrial Cancer × Letrozole × Clear all
NCT05705505 2023-12-12

Study of Narazaciclib (ON 123300) Plus Letrozole in Endometrial Cancer and Other Gynecologic Malignancies

Traws Pharma, Inc.

Phase 1/2 Unknown
60 enrolled
Gynecologic

Endometrioid Endometrial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡